Folate receptor alpha as a tumor target in epithelial ovarian cancer

Gynecologic Oncology

Volumn 108, Issue 3, 2008, Pages 619-626

  Kalli, Kimberly R ^a   Oberg, Ann L ^a   Keeney, Gary L ^a   Christianson, Teresa J H ^a   Low, Philip S ^b   Knutson, Keith L ^c   Hartmann, Lynn C ^a  

^a Mayo Clinic   (United States)

^b PURDUE UNIVERSITY   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

Folate receptor; Ovarian cancer

Indexed keywords

CYCLOPHOSPHAMIDE; FOLATE RECEPTOR; FOLATE RECEPTOR ALPHA; PLATINUM; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORPHOLOGY; CANCER STAGING; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; EPITHELIUM TUMOR; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 39249085399     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.11.020     Document Type: Article

References (41)

1. Elnakat H., and Ratnam M. Role of folate receptor genes in reproduction and related cancers. Front Biosci 11 (2006) 506-519
2. Sandoval R.M., Kennedy M.D., Low P.S., and Molitoris B.A. Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy. Am J Physiol Cell Physiol 287 (2004) C517-C526
3. Kamen B.A., and Smith A.K. A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev 56 (2004) 1085-1097
4. Weitman S.D., Lark R.H., Coney L.R., et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52 (1992) 3396-3401
5. Leamon C.P., and Low P.S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A 88 (1991) 5572-5576
6. Salazar M.D., and Ratnam M. The folate receptor: what does it promise in tissue-targeted therapeutics?. Cancer Metastasis Rev 26 (2007) 141-152
7. Reddy J.A., Allagadda V.M., and Leamon C.P. Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr Pharm Biotechnol 6 (2005) 131-150
8. Parker N., Turk M.J., Westrick E., Lewis J.D., Low P.S., and Leamon C.P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338 (2005) 284-293
9. Knutson K.L., Krco C., Goodman K., et al. T cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol 24 (2006) 4254-4261
10. Ebel W., Routhier E.L., Foley B., et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 7 (2007) 6
11. Toffoli G., Russo A., Gallo A., et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 79 (1998) 121-126
12. Ozols R.F., Rubin S.C., Thomas G.M., and Robboy S.J. Epithelial ovarian cancer. In: Hoskins W.J., Perez C.A., Young R.C., Barakat R.R., Markman M., and Randall M.E. (Eds). Principles and practice of gynecologic oncology. 4th ed. (2005), Lippincott Williams & Wilkins, Philadelphia, PA 895-987
13. Chien J., Aletti G., Baldi A., et al. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest 116 (2006) 1994-2004
14. Franklin W.A., Waintrub M., Edwards D., et al. New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer Suppl 8 (1994) 89-95
15. Kelemen L.E., Sellers T.A., Keeney G.L., and Lingle W.L. Multivitamin and alcohol intake and folate receptor alpha expression in ovarian cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 2168-2172
16. Cannistra S.A. Cancer of the ovary. N Engl J Med 351 (2004) 2519-2529
17. Aletti G.D., Gallenberg M.M., Cliby W.A., Jatoi A., and Hartmann L.C. Current management strategies for ovarian cancer. Mayo Clin Proc 82 (2007) 751-770
18. Diaz-Montes T.P., and Bristow R.E. Secondary cytoreduction for patients with recurrent ovarian cancer. Curr Oncol Rep 7 (2005) 451-458
19. Chi D.S., McCaughty K., Diaz J.P., et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106 (2006) 1933-1939
20. Winter III W.E., Maxwell G.L., Tian C., et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25 (2007) 3621-3627
21. Hartmann L.C., Keeney G.L., Lingle W.L., et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 121 (2007) 938-942
22. Allard J.E., Risinger J.I., Morrison C., et al. Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecol Oncol 107 1 (2007) 52-57
23. Yang R., Kolb E.A., Qin J., et al. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res 13 (2007) 2557-2567
24. Bottero F., Tomassetti A., Canevari S., Miotti S., Menard S., and Colnaghi M.I. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res 53 (1993) 5791-5796
25. Bottero F., Tomassetti A., Canevari S., Miotti S., Menard S., and Colnaghi M.I. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res 53 (1993) 5791-5796
26. Jhaveri M.S., Rait A.S., Chung K.N., Trepel J.B., and Chang E.H. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther 3 (2004) 1505-1512
27. Figini M., Ferri R., Mezzanzanica D., et al. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther 10 (2003) 1018-1025
28. Leamon C.P., Reddy J.A., Vlahov I.R., et al. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int J Cancer (2007)
29. Reddy J.A., Westrick E., Vlahov I., Howard S.J., Santhapuram H.K., and Leamon C.P. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Cancer Chemother Pharmacol 58 (2006) 229-236
30. Hilgenbrink A.R., and Low P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 94 (2005) 2135-2146
31. Muller C., Hohn A., Schubiger P.A., and Schibli R. Preclinical evaluation of novel organometallic 99mTc-folate and 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting. Eur J Nucl Med Mol Imaging 33 (2006) 1007-1016
32. Okarvi S.M., and Jammaz I.A. Preparation and in vitro and in vivo evaluation of technetium-99m-labeled folate and methotrexate conjugates as tumor imaging agents. Cancer Biother Radiopharm 21 (2006) 49-60
33. 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 44 (2003) 700-707
34. Roy E.J., Gawlick U., Orr B.A., and Kranz D.M. Folate-mediated targeting of T cells to tumors. Adv Drug Deliv Rev 56 (2004) 1219-1231
35. Kranz D.M., Patrick T.A., Brigle K.E., Spinella M.J., and Roy E.J. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis. Proc Natl Acad Sci U S A 92 (1995) 9057-9061
36. Dixit V., Van den Bossche J., Sherman D.M., Thompson D.H., and Andres R.P. Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells. Bioconjug Chem 17 (2006) 603-609
37. Hasegawa K., Nakamura T., Harvey M., et al. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 12 (2006) 6170-6178
38. Campbell I.G., Jones T.A., Foulkes W.D., and Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res 51 (1991) 5329-5338
39. Ross J.F., Chaudhuri P.K., and Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 73 (1994) 2432-2443
40. Holm J., Hansen S.I., Hoier-Madsen M., Helkjaer P.E., and Bzorek M. Folate receptor in malignant effusions of ovarian carcinoma. Apmis 103 (1995) 663-670
41. Holm J., Hansen S.I., Hoier-Madsen M., Birn H., and Helkjaer P.E. High-affinity folate receptor in human ovary, serous ovarian adenocarcinoma, and ascites: radioligand binding mechanism, molecular size, ionic properties, hydrophobic domain, and immunoreactivity. Arch Biochem Biophys 366 (1999) 183-191